CR20190375A - Anticuerpos anti-tgf-beta y su uso - Google Patents

Anticuerpos anti-tgf-beta y su uso

Info

Publication number
CR20190375A
CR20190375A CR20190375A CR20190375A CR20190375A CR 20190375 A CR20190375 A CR 20190375A CR 20190375 A CR20190375 A CR 20190375A CR 20190375 A CR20190375 A CR 20190375A CR 20190375 A CR20190375 A CR 20190375A
Authority
CR
Costa Rica
Prior art keywords
tgf
antibody
conditions
beta antibodies
cancers
Prior art date
Application number
CR20190375A
Other languages
English (en)
Inventor
Rao Koduri
Patrick Finn
Feng Liu
Natalia Malkova
Huawei Qiu
Joachim Theilhaber
Kevin Browen
Christopher Winter
Richard C Gregory
Parminder Mankoo
Jack R Pollard
Gary Shapiro
Marcella Yu
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Priority claimed from PCT/IB2018/000088 external-priority patent/WO2018134681A1/en
Publication of CR20190375A publication Critical patent/CR20190375A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención proporciona un anticuerpo pan-TGF-ß mejorado para el tratamiento de afecciones que están mediadas por TGF-ß, incluyendo enfermedades autoinmunitarias, afecciones fibróticas, y cánceres. También se proporcionan usos y usos del anticuerpo junto con otros agentes inmunomoduladores tales como un anticuerpo anti-PD-1.The invention provides an improved pan-TGF-ß antibody for treatment of conditions that are mediated by TGF-ß, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.
CR20190375A 2017-01-20 2018-01-19 Anticuerpos anti-tgf-beta y su uso CR20190375A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762448800P 2017-01-20 2017-01-20
EP17305061 2017-01-20
PCT/IB2018/000088 WO2018134681A1 (en) 2017-01-20 2018-01-19 Anti-tgf-beta antibodies and their use

Publications (1)

Publication Number Publication Date
CR20190375A true CR20190375A (es) 2019-12-17

Family

ID=61656071

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190375A CR20190375A (es) 2017-01-20 2018-01-19 Anticuerpos anti-tgf-beta y su uso

Country Status (22)

Country Link
US (4) US10766955B2 (es)
JP (4) JP7213186B2 (es)
CN (2) CN117417939A (es)
AU (2) AU2018209391B2 (es)
BR (1) BR112019014787A2 (es)
CA (1) CA3050845A1 (es)
CL (1) CL2019002011A1 (es)
CO (1) CO2019008946A2 (es)
CR (1) CR20190375A (es)
DO (1) DOP2019000191A (es)
EC (1) ECSP19059553A (es)
IL (3) IL311866B2 (es)
MA (1) MA47311A (es)
MX (2) MX2019008551A (es)
MY (1) MY200751A (es)
NZ (1) NZ796440A (es)
PE (1) PE20200734A1 (es)
PH (1) PH12019501635A1 (es)
SG (1) SG11201906660TA (es)
TW (3) TW202506185A (es)
UY (1) UY37575A (es)
ZA (1) ZA201904494B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
AR110755A1 (es) 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
BR112021000065A2 (pt) * 2018-07-10 2021-04-06 Sanofi Terapias de combinação contra câncer direcionando cd38 e tgf-beta
WO2020047333A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
CN112996805A (zh) 2018-08-30 2021-06-18 Hcw生物科技公司 多链嵌合多肽和其用途
AU2019406214A1 (en) * 2018-12-21 2021-08-05 Northwestern University Use of annexins in preventing and treating muscle membrane injury
EP3739588A1 (en) * 2019-05-13 2020-11-18 Koninklijke Philips N.V. Assessment of multiple signaling pathway activity score in airway epithelial cells to predict airway epithelial abnormality and airway cancer risk
AU2020294797B2 (en) 2019-06-21 2025-12-18 Immunitybio, Inc. Multi-chain chimeric polypeptides and uses thereof
WO2021163299A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Chromatography resin and uses thereof
CA3169243A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
CN116670163A (zh) 2020-02-11 2023-08-29 Hcw生物科技公司 治疗年龄相关疾病和炎性疾病的方法
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
AU2021262794B2 (en) 2020-04-29 2026-06-18 Immunitybio, Inc. Anti-CD26 proteins and uses thereof
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
US20220119513A1 (en) * 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
CN112940119B (zh) * 2021-04-26 2022-05-20 北京芳渟阳生生物科技有限公司 一种单克隆抗体及其与间充质干细胞外泌体的联合应用
TW202317185A (zh) 2021-06-18 2023-05-01 美商健臻公司 抗ＴＧＦ－β抗體配製品及其用途
JP7892764B2 (ja) 2021-08-11 2026-07-21 イミュニティーバイオ インコーポレイテッド 多重鎖キメラポリペプチド及び肝疾患の治療におけるその使用
CN115707716A (zh) * 2021-08-18 2023-02-21 丹生医药技术(上海)有限公司 一种TGF-β/VEGF双功能抗体融合蛋白
US20230144192A1 (en) * 2021-11-01 2023-05-11 Genzyme Corporation Treatment of osteogenesis imperfecta
EP4507712A1 (en) 2022-04-13 2025-02-19 ImmunityBio, Inc. Multi-chain chimeric polypeptide for use in the treatment of circardian clock gene disorder
US12594323B2 (en) 2022-04-13 2026-04-07 Immunitybio, Inc. Methods of reducing neuroinflammation
CN115508565B (zh) * 2022-10-20 2024-11-15 成都医学院第一附属医院 Cilp1作为肾纤维化生物标志物的应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
CA2280957A1 (en) 1997-02-14 1998-08-20 Leslie Orgel Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
MY131805A (en) 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
EP1074563A1 (en) 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
US20020063763A1 (en) 2000-11-29 2002-05-30 Mantell David Allen Apparatus and method for removing air bubbles from an ink jet printhead
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
KR20050094832A (ko) 2002-12-31 2005-09-28 알투스 파마슈티컬스 인코포레이티드 단백질 결정과 이온성 중합체를 함유하는 복합체
JP2006525362A (ja) 2003-04-30 2006-11-09 ジェンザイム コーポレーション 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用
WO2005010049A2 (en) 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
PL1759001T3 (pl) 2004-04-21 2011-09-30 Alexion Pharma Inc Koniugaty dostarczane do kości i sposób ich zastosowania do nakierowywania białek do kości
CA2597098C (en) 2005-02-08 2016-08-02 Steven R. Ledbetter Antibodies to tgfbeta
TW200714289A (en) 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
AU2008255352B2 (en) * 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
EA021967B1 (ru) 2008-01-03 2015-10-30 Дзе Скриппс Рисерч Инститьют Доставка антител посредством модульного домена распознавания
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
WO2010072691A1 (en) 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
US20120294868A1 (en) 2009-04-24 2012-11-22 Edwards James R Anti-tgf-beta induction of bone cell function and bone growth
US8993524B2 (en) 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
LT2691417T (lt) * 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
EP2714735B1 (en) 2011-06-03 2021-07-21 XOMA Technology Ltd. Antibodies specific for tgf-beta
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
KR20140084201A (ko) 2011-10-19 2014-07-04 알렉시온 파마 홀딩 알칼리성 포스파타제 및/또는 나트륨이뇨 펩티드를 포함하는 조성물 및 그의 사용 방법
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
MX361773B (es) 2012-05-31 2018-12-17 Innate Pharma Agentes de ligación a tlr3.
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CA2886607A1 (en) * 2012-10-17 2014-04-24 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
AU2014235933B2 (en) * 2013-03-20 2019-01-24 Baylor College Of Medicine Methods for treating osteogenesis imperfecta
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
ES2763429T5 (es) * 2013-12-17 2023-06-21 Hoffmann La Roche Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
EP3119419B1 (en) 2014-03-17 2019-04-03 Piotr Jachimczak Combination for use in a method of treating cancer
CN107428825A (zh) 2014-10-10 2017-12-01 创祐生技股份有限公司 治疗及/或预防肿瘤生长、侵袭及/或转移的方法
SG11201702401RA (en) * 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
TWI733661B (zh) * 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
ES2820768T3 (es) 2015-04-03 2021-04-22 Xoma Technology Ltd Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
HRP20201334T1 (hr) 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
WO2017011773A2 (en) 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
US20200231652A1 (en) 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
US20190216943A1 (en) 2016-08-11 2019-07-18 Precithera, Inc. Tgf-beta antagonist conjugates
AR110755A1 (es) 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途

Also Published As

Publication number Publication date
IL311866A (en) 2024-06-01
TWI787230B (zh) 2022-12-21
PE20200734A1 (es) 2020-07-23
IL268112A (en) 2019-09-26
IL268112B2 (en) 2025-09-01
CA3050845A1 (en) 2018-07-26
IL311866B2 (en) 2026-03-01
MX2019008551A (es) 2020-01-27
CO2019008946A2 (es) 2019-09-30
UY37575A (es) 2018-10-31
JP2026036696A (ja) 2026-03-05
IL311866B1 (en) 2025-11-01
JP7411832B2 (ja) 2024-01-11
AU2024264593A1 (en) 2024-12-05
BR112019014787A2 (pt) 2020-02-27
US20180244763A1 (en) 2018-08-30
MA47311A (fr) 2019-11-27
JP2023052376A (ja) 2023-04-11
AU2018209391B2 (en) 2024-08-15
DOP2019000191A (es) 2019-10-15
JP7844425B2 (ja) 2026-04-13
IL268112B1 (en) 2025-05-01
TWI856437B (zh) 2024-09-21
TW201833135A (zh) 2018-09-16
CN110520441B (zh) 2023-11-14
ECSP19059553A (es) 2019-08-30
PH12019501635A1 (en) 2019-11-04
TW202506185A (zh) 2025-02-16
US20200399358A1 (en) 2020-12-24
NZ796440A (en) 2025-12-19
CN117417939A8 (zh) 2024-07-12
ZA201904494B (en) 2020-12-23
CN110520441B8 (zh) 2024-07-09
US20250026821A1 (en) 2025-01-23
US11242384B2 (en) 2022-02-08
US20220195026A1 (en) 2022-06-23
CN117417939A (zh) 2024-01-19
JP2024038040A (ja) 2024-03-19
MX2023002588A (es) 2023-03-22
IL323799A (en) 2025-12-01
NZ756431A (en) 2025-03-28
JP2020514310A (ja) 2020-05-21
SG11201906660TA (en) 2019-08-27
JP7213186B2 (ja) 2023-01-26
US12049496B2 (en) 2024-07-30
AU2018209391A1 (en) 2019-09-05
CL2019002011A1 (es) 2019-11-22
TW202313678A (zh) 2023-04-01
CN110520441A (zh) 2019-11-29
MY200751A (en) 2024-01-13
US10766955B2 (en) 2020-09-08

Similar Documents

Publication Publication Date Title
DOP2019000191A (es) Anticuerpos anti-tgf-beta y su uso
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
DOP2021000022A (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
WO2018134681A8 (en) Anti-tgf-beta antibodies and their use
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CO2017004516A2 (es) Anticuerpos anti-ox40 humanizados
MX382216B (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo.
CL2018001384A1 (es) Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales
PH12020500576A1 (en) Method of treating cancers with antagonistic anti-pd-1 antibodies
CL2019001043A1 (es) Anticuerpos anti-il-33 y usos de los mismos.
GEAP202315361A (en) Antibodies against signal-regulatory protein alpha and methods of use
CL2017001090A1 (es) Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
NI201700016A (es) Conjugados de fármacos con anticuerpos anti-cdh6
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
MX2017005977A (es) Anticuerpos biespecificos y metodos de uso en oftalmologia.
MX2017007242A (es) Receptores de antigeno quimerico que se dirigen al receptor acoplado a la proteina g y sus usos.
MX2022015250A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2018009499A (es) Anticuerpos monoclonales especificos de egfl6 y metodos de su uso.
CO2019002550A2 (es) Anticuerpos anti-gm-csf y usos de los mismos
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
PY1802434A (es) "anticuerpos anti-tgf-beta y su uso"